RT Journal Article
T1 Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
A1 Frezza, Anna Maria
A1 Jones, Robin L
A1 Lo-Vullo, Salvatore
A1 Asano, Naofumi
A1 Lucibello, Francesca
A1 Ben-Ami, Eytan
A1 Ratan, Ravin
A1 Teterycz, Pawel
A1 Boye, Kjetil
A1 Brahmi, Mehdi
A1 Palmerini, Emanuela
A1 Fedenko, Alexander
A1 Vincenzi, Bruno
A1 Brunello, Antonella
A1 Desar, Ingrid M E
A1 Benjamin, Robert S
A1 Blay, Jean Yves
A1 Broto, Javier Martin
A1 Casali, Paolo G
A1 Gelderblom, Hans
A1 Grignani, Giovanni
A1 Gronchi, Alessandro
A1 Hall, Kirsten Sundby
A1 Mir, Olivier
A1 Rutkowski, Piotr
A1 Wagner, Andrew J
A1 Anurova, Olga
A1 Collini, Paola
A1 Dei-Tos, Angelo P
A1 Flucke, Uta
A1 Hornick, Jason L
A1 Lobmaier, Ingvild
A1 Philippe, Terrier
A1 Picci, Piero
A1 Ranchere, Dominique
A1 Renne, Salvatore L
A1 Sbaraglia, Marta
A1 Thway, Khin
A1 Wagrodzki, Michal
A1 Wang, Wei-Lien
A1 Yoshida, Akihiko
A1 Mariani, Luigi
A1 Kawai, Akira
A1 Stacchiotti, Silvia
K1 Anthracyclines
K1 Antineoplastic Combined Chemotherapy Protocols
K1 Deoxycytidine
K1 Pyrimidines
K1 Remission Induction
K1 Gemcitabine
AB Epithelioid sarcoma (ES) is an exceedingly rare malignant neoplasm with distinctive pathologic, molecular, and clinical features as well as the potential to respond to new targeted drugs. Little is known on the activity of anthracycline-based regimens, gemcitabine-based regimens, and pazopanib in this disease. To report on the activity of anthracycline-based regimens, gemcitabine-based regimens, and pazopanib in patients with advanced ES. Seventeen sarcoma reference centers in Europe, the United States, and Japan contributed data to this retrospective analysis of patients with locally advanced/metastatic ES diagnosed between 1990 and 2016. Local pathological review was performed in all cases to confirm diagnosis according to most recent criteria. All patients included in the study received anthracycline-based regimens, gemcitabine-based regimens, or pazopanib. Response was assessed by RECIST. Progression-free survival (PFS) and overall survival (OS) were computed by Kaplan-Meier method. Classic and proximal subtypes were defined based on morphology (according to 2013 World Health Organization guidelines). Overall, 115 patients were included, 80 (70%) were men and 35 (30%) were women, with a median age of 32 years (range, 15-77 years). Of the 115 patients with ES, 85 were treated with anthracycline-based regimens, 41 with gemcitabine-based regimens, and 18 with pazopanib. Twenty-four received more than 1 treatment. Median follow-up was 34 months. Response rate for anthracycline-based regimens was 22%, with a median PFS of 6 months. One complete response (CR) was reported. A trend toward a higher response rate was noticed in morphological proximal type (26%) vs classic type (19%) and in proximal vs distal primary site (26% vs 18%). The response rate for gemcitabine-based regimens was 27%, with 2 CR and a median PFS of 4 months. In this group, a trend toward a higher response rate was reported in classic vs proximal morphological type (30% vs 22%) and in distal vs proximal primary site (40% vs 14%). In the pazopanib group, no objective responses were seen, and median PFS was 3 months. This is the largest retrospective series of systemic therapy in ES. We confirm a moderate activity of anthracycline-based and gemcitabine-based regimens in ES, with a similar response rate and PFS in both groups. The value of pazopanib was low. These data may serve as a benchmark for trials of novel agents in ES.
PB American Medical Association
YR 2018
FD 2018-04-12
LK http://hdl.handle.net/10668/12507
UL http://hdl.handle.net/10668/12507
LA en
NO Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, et al. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. JAMA Oncol. 2018 Sep 1;4(9):e180219.
DS RISalud
RD Apr 11, 2025